Parexel, a Privately Owned company headquartered in the US, was founded in 1982 and employs approximately 19,050 individuals. Functioning as a clinical research organization (CRO), it specializes in contract research, consulting, medical communications, and technology solutions. The company serves the worldwide pharmaceutical, biotechnology, and medical device industries, providing a range of Phase I to IV clinical development services. Its global professionals collaborate with biopharmaceutical organizations, innovators, and sites to design and deliver clinical trials, leveraging clinical, regulatory, and therapeutic expertise with a focus on advancing clinical research and making the clinical trial process efficient.
On May 1, 2026, Parexel acquired Vitrana, an AI-enabled pharmacovigilance (PV) technology provider, to expand its patient safety operations and integrate Vitrana's system-agnostic platform into its clinical development ecosystem. This acquisition aims to create a unified model that combines safety services and technology, leveraging intelligent automation and artificial intelligence to accelerate PV processes, deliver quality, and enhance compliance. Earlier that day and the previous day, reports confirmed that Parexel, which is backed by EQT and Goldman Sachs Asset Management, bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed sum. The deal expands Parexel's technology capabilities with a system-agnostic platform designed to integrate with any safety database.
Subscribe for full access to Parexel's products in full detail 
